2016 issue 3


Volume 32, issue 3

Review article

Long-acting aripiprazole in the treatment of schizophrenia; practical aspects

Marek Jarema1, Adam Wichniak1
1. Instytut Psychiatrii i Neurologii w Warszawie, III Klinika Psychiatryczna
Farmakoterapia w Psychiatrii i Neurologii 2016, 32 (3), 145–156
Date of publication: 21-11-2016
DOI: http://dx.medra.org/10.17393/fpn.2016.09.004
Keywords: Schizophrenia, Pharmacotherapy, Aripiprazole, Long-acting injections


Treatment compliance is one of the most important factors in the course of antipsychotic therapy. Providing the fact that noncompliance or partial compliance with antipsychotic treatment is significant and may be found in even more than one half of patients, the use of long-acting injections of antipsychotics (LAI) becomes a more frequent form of treatment. The aim of the paper is to present the overview of studies indicating how the introduction of long-acting aripiprazole creates the new perspectives in antipsychotic treatment and how to initiate the treatment with this drug.
Aripiprazole is currently the only available antipsychotic drug showing partial agonism toward the D2 receptors. In clinical practice, this drug is characterised by lower propensity for extrapyramidal side-effects, sedation, weight gain, orthostatic hypotension, and cholinolytic symptoms in comparison to other antipsychotics. Aripiprazole LAI is indicated for maintenance treatment in adult patients with schizophrenia, who have been stabilised with oral aripiprazole treatment. The therapy with aripiprazole LAI should be initiated by injection of 400 mg and this dose should be repeated every month; this dose is considered the therapeutic one. After the first injection the oral supplementation with aripiprazole 10–20 mg/day for 14 days is needed.

Address for correspondence:
Marek Jarema
Instytut Psychiatrii i Neurologii
III Klinika Psychiatryczna
ul. Sobieskiego 9, 02-957 Warszawa Poland
phone: +48 22 842 40 87
email: jarema@ipin.edu.pl